OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999.

TAIPEI, Taiwan, December 18, 2019 ─ OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced the initiation of a Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT04084366) of OBI-999, an antibody drug conjugate (ADC) targeting Globo H, a glycolipid antigen overexpressed in multiple tumor types. Patients with solid tumors including gastric, pancreatic, colorectal and esophageal […]

This article is password protected.

To view the content, please enter your password in the field below